One hundred years have passed since Warburg discovered alterations in cancer
metabolism, more than 70 years since Sidney Farber introduced anti-folates that …

Patient‐derived cancer cells (PDCs) and patient‐derived xenografts (PDXs) are often used
as tumor models, but have many shortcomings. PDCs not only lack diversity in terms of cell …

Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil (MMF), an
immunosuppressive drug approved for the prophylaxis of allograft rejection in transplant …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death
globally and liver transplantation (LT) can serve as the best curative treatment option …

Simple Summary While hepatocellular carcinoma (HCC) is inextricably linked to underlying
cirrhosis due to chronic viral hepatitis, alcohol consumption, and non-alcoholic fatty liver …

Background & Aims Liver cancer-related deaths are projected to exceed one million
annually by 2030. Existing therapies have significant limitations, including severe side …

Primary liver cancer (PLC) is a primary cause of cancer-related death worldwide, and novel
treatments are needed due to the limited options available for treatment and tumor …

Autoimmune hepatitis (AIH) is an inflammatory liver disease of unknown etiology caused by
an autoimmune mechanism. It can occur in all age groups and manifest as almost every type …

Hepatocellular carcinoma (HCC) is one of the most aggressive tumours with marked fibrosis.
Mycophenolate mofetil (MMF) was well‐established to have antitumour and anti‐fibrotic …

Oncolytic adenovirus (OA) has attracted increasing attention due to their specific
proliferation in tumour cells and resulting in lysis of tumour cells. To further improve the …